Skip to main content
Fig. 3 | Journal of Neurodevelopmental Disorders

Fig. 3

From: A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)

Fig. 3

Changes from baseline in ABC-CFXS subscale scores. Least square mean (LSM) changes from baseline in ABC-CFXS subscale scores are shown for each treatment group along with the LSM treatment differences. A Results from the full analysis set. B Results from the patients who had ≥ 90% methylation of the promoter region of the FMR1 gene. FAS, full analysis set

Back to article page